Chaudhuri Sarbani 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Rocket Pharmaceuticals (RCKT) Officer Sarbani Chaudhuri Receives Awards
What Happened
Sarbani Chaudhuri, Rocket Pharmaceuticals' Chief Commercial & Medical Affairs Officer, was granted equity awards on February 11, 2026: 125,924 restricted stock units (RSUs) and a derivative option covering 189,076 shares. Both grants are reported as acquired at $0 on the Form 4 (i.e., no cash purchase reported).
Key Details
- Transaction date: February 11, 2026; Form 4 filed Feb 13, 2026 (not marked as late).
- Awards: 125,924 RSUs (reported as Award/Acquisition, code A) and a 189,076‑share option (reported as derivative Award/Acquisition, code A). Reported price per share: $0 (grant/award).
- Vesting: For both the RSUs and the option, one‑third vests on February 11, 2027; the remaining shares vest in equal quarterly installments over the following two years. Option vesting is subject to continued employment.
- Footnotes: Holdings include RSUs that convert one‑for‑one into common stock. The option is a right to purchase the stated shares (derivative), per the filing.
- Shares owned after the transaction: not specified in the provided filing details.
Context
These are grants/awards (not open‑market purchases or sales). RSUs convert to common shares when vested; the option gives a right to buy shares as it vests. Grants are common for executive compensation and do not by themselves signal a buy/sell decision. The filing shows the award amounts and vesting schedule but does not indicate any immediate exercise or sale.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-11+125,924→ 285,160 total - Award
Stock Option (Right to Buy)
[F3]2026-02-11+189,076→ 189,076 totalExercise: $3.24Exp: 2036-02-11→ Common Stock (189,076 underlying)
Footnotes (3)
- [F1]Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
- [F2]Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F3]This option represents a right to purchase a total of 189,076 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.